Exelixis’ Cabometyx (cabozantinib) Receives FDA Approval for Previously Treated Hepatocellular Carcinoma (HCC)

 Exelixis’ Cabometyx (cabozantinib) Receives FDA Approval for Previously Treated Hepatocellular Carcinoma (HCC)

Exelixis’ Cabometyx (cabozantinib) Receives FDA Approval for Previously Treated Hepatocellular Carcinoma (HCC)

Shots:
  • The approval is based on P-III CELESTIAL study results assessing Cabometyx (60 mg, qd) vs PBO in 760 patients in a ratio (2:1) with 2L advanced HCC who previously received sorafenib
  • P-III CELESTIAL study results: mOS (10.2 vs 8.0 mos.); mPFS (5.2 vs 1.9 mos.); ORR (4% vs 0.4%); Disease control (64% vs 33%), Presented at ASCO-GI Jan, 2018
  • Cabometyx (cabozantinib)is a TKI approved by the US FDA and EU for renal cell carcinoma (RCC) & advanced RCC in adults received prior VEGF-targeted therapy respectively. In Dec  2018, Exelixis initiated P-III COSMIC-312 study for evaluation of cabozantinib + atezolizumab vs sorafenib in 1L untreated advanced HCC

Click here to read full press release/ article | Ref: Exelixis| Image: Coa Pharmacy

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post